3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1/2
1
Status
Completed
2
Active not recruiting
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
22
Gastrointestinal
16
Gynecologic
5
Head & Neck
4
Tumor-Agnostic
3
Thoracic
3
Other hematologic neoplasm
2
Genitourinary
2
Endocrine
2
Other solid neoplasm
1
Other
1
Lymphoid
1
CNS
1
Conditions
Urinary Incontinence
1
Prostatic Neoplasms
1
Castration-resistant Prostate Cancer
1
Interventions
Docetaxel
205
Prednisone
151
enzalutamide
128
Gemcitabine
122
Radiotherapy
116
Sunitinib
112
Cisplatin
102
Leuprolide
98
pembrolizumab
95
Abiraterone Acetate
94
bicalutamide
87
Nivolumab
85
Goserelin
83
Sorafenib
80
Paclitaxel
79
Carboplatin
77
Everolimus
72
Bevacizumab
71
Magnetic Resonance Spectroscopy
65
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
61
pazopanib
56
radium Ra 223 dichloride
50
Ipilimumab
49
Zoledronic Acid
47
Radiosurgery
43
Cyclophosphamide
43
Filgrastim
42
abiraterone
41
gallium 68 PSMA-11
40
Surveys and Questionnaires
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Control Groups
×
Genitourinary
×
Clear all
NCT05549778
2023-07-11
PEACe
Jiangnan University
Phase 1/2
Completed
12 enrolled
NCT04862533
2022-12-16
BELA
University Hospital Olomouc
Phase NA
Completed
80 enrolled